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AbstrAct
To characterise the different types of pulmonary 
hypertension (PH) among idiopathic inflammatory 
myopathy (IIM). A retrospective case series with 
assessment of PH by right heart catheterisation, extent of 
interstitial lung disease (ILD) and outcome of vasoactive 
therapy.The group of patients with IIM with PH (n=9) 
showed a median age at PH diagnosis of 62 years (IQR 
48–71 years; eight women), seven diagnosed with 
polymyositis and two with dermatomyositis; median 
disease duration of 5.7 years and five patients with a 
positive anti-Jo1 antibody. We found one patient to be 
classified in PH WHO group 2 (left heart disease), five 
patients in WHO group 3 (lung disease) and three patients 
in WHO group 1 (pulmonary arterial hypertension (PAH)). 
During median observed follow-up of 24 months, mortality 
for the total group was 44%. Surprisingly, we found a 
relevant group (33%) of patients with IIM who suffered 
from non-ILD-PH, which reflects the presence of PAH 
phenotype. This result should lead to more awareness 
among treating physicians that complaints of dyspnoea 
among patient with IIM could be related to PAH and not 
only ILD. The role of vasoactive therapy remains to be 
defined in patients with IIM suffering from PAH or PH-ILD.
IntroductIon
Pulmonary hypertension (PH) is a life-threat-
ening condition presenting with symptoms 
like breathlessness, fatigue and syncope.1 
PH can occur as a complication of systemic 
autoimmune diseases.2–4 The association 
with polymyositis (PM) and dermatomyositis 
(DM), together classified as idiopathic inflam-
matory myopathy (IIM), is not well known.5 
So far, only a few cases reported on PH in 
patients with IIM.6–11 However, two recent 
cohort studies among antisynthetase patients 
revealed a prevalence of PH ranging from 
7.9% to 14.8% with a worsened prognosis.12 13 
These study results reflect the clinical rele-
vance of PH as a complication of IIM.
Patients with PH can be classified according 
to the WHO classification in pulmonary 
arterial hypertension (PAH) (group 1), PH 
associated to left heart disease (group 2), PH 
associated to lung disease (group 3), chronic 
thromboembolic PH (group 4) and PH with 
unclear mechanism (group 5).14 The cause of 
PH in patients with IIM is however still unclear. 
Although interstitial lung disease (ILD) is 
frequently found among patients with IIM, 
occurring in up to 65% of the patients,15 the 
question is whether this lung disease explains 
the presence of PH in all patients with IIM. 
In addition, data on long-term follow-up are 
scarce.
For this, we describe the clinical character-
istics and follow-up of nine patients with IIM 
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Key messages
What is already known about this subject?
 ► Pulmonary hypertension (PH) is a life-threatening 
condition and is associated with patients 
with  idiopathic inflammatory myopathy (IIM). 
Although interstitial lung disease (ILD) is frequently 
found among patients with IIM patients, the question 
is whether this lung disease explains the presence of 
PH in all patients with IIM.
What does this study add?
 ► Surprisingly, we found a relevant group (33%) of 
patients with IIM who  suffered from non-ILD-PH, 
which reflects the presence of pulmonary arterial 
hypertension (PAH) phenotype. The role of vasoactive 
therapy remains to be defined in patients with IIM 
suffering from PAH or PH-ILD.
How might this impact on clinical practice?
 ► This result should lead to more awareness among 
treating physicians that complaints of dyspnoea 
among patients with IIM could be related to PAH and 
not only ILD.
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with PH and investigated the cause and effect of PH in 
these patients.
Methods
This is a retrospective case series which consisted of 
patients with IIM (n=9) with PH of two Dutch univer-
sity hospitals (Radboud University Medical Center, 
Nijmegen) (n=4) and (VU University Medical Center, 
Amsterdam) (n=5) which are both expert centres for PH. 
According to Dutch law and regulations, the study was 
exempted from approval of a medical ethical committee 
and no informed consent was required since this was an 
observational, non-interventional study.
Participants
All patients with IIM fulfilled at least the criteria for prob-
able IIM according to the European Neuromuscular 
Centre (ENMC) classification criteria.16 PH was defined 
as an increase in mean pulmonary arterial pressure 
(mPAP) ≥25 mm Hg assessed with right heart catheterisa-
tion (RHC).14 All known patients with IIM and PH were 
included at both medical centres (VU University Medical 
Center, a registry of patients with PH; Radboud Univer-
sity Medical Center, Myositis Nijmegen cohort).
Interstitial lung disease
Presence of extensive ILD was defined as signs of 
pulmonary fibrosis on high-resolution computed tomog-
raphy (HRCT) scan with >10% lung involvement. Limited 
ILD was defined as extent of lung parenchymal involve-
ment ≤10% on HRCT which is a conservative cut-off in 
comparison with staging system of Goh et al (≤20%).17 In 
remaining cases with an indeterminate extent on HRCT, 
an abnormal pulmonary function test (total lung capacity 
(TLC) <70% predicted) was used to classify extensive ILD. 
A blinded pulmonologist (AV-N) retrospectively reviewed 
all available HRCT scans using the Wells method to score 
the presence and extent of ILD.18
haemodynamics rhc
Based on pulmonary capillary wedge pressure (PCWP), 
PH can be divided into precapillary PH (PCWP ≤15 mm 
Hg) and postcapillary PH (PCWP >15 mm Hg), which 
can be related to different clinical causes.14 Patients 
with precapillary PH and limited ILD were defined as 
non-ILD-PH (reflecting PAH), whereas patients with 
precapillary PH and extensive ILD as ILD-PH. Other 
parameters which were assessed by RHC were PCWP, 
cardiac output and pulmonary vascular resistance (PVR). 
Outcome of vasoactive therapy in patients with PH-IIM 
was evaluated by available information on mortality, 
hospital admissions, therapy adjustments and alterations 
of 6 min walking test (6MWT) or WHO functional class 
(WHO-FC).19 The WHO-FC system grades severity of 
limitations due to PH on a scale of 1 (no limitations) to 4 
(limitation of all exercise).
cAse rePort
Patients
Our cohort consists of nine patients, of which seven 
patients were diagnosed with polymyositis and two with 
dermatomyositis. The median age at diagnosis of PH was 
62 years (IQR 48–68 years; eight women). The median 
disease duration of IIM at diagnosis of PH was 5.7 years 
(IQR 3–10.3 years). In five patients, anti-Jo1 autoanti-
body was present (table 1).
Interstitial lung disease
Signs of pulmonary fibrosis on HRCT scans were present 
in seven patients (88%), with scans performed in eight out 
of nine patients. All seven patients had a precapillary PH. 
A Wells score of 3, presenting dominance of a reticular 
pattern (ie, fibrosis) was present in three (38%) patients. 
The median lung involvement was 50% of the surface 
(range 0%–90%) with four patients ≥70% lung involve-
ment on the scans. Three patients (37%) displayed none 
or limited lung involvement (surface ≤10%) (table 1, 
patients 3, 5 and 9).
Ph characterisation
Eight patients presented with precapillary PH. Chronic 
thromboembolic PH and multifactorial PH causes were 
excluded. One patient was diagnosed with postcapillary 
PH caused by severe aorta valve stenosis, PH WHO group 
2 (table 1).
Combining information on ILD with RHC data demon-
strates that five out of eight precapillary patients with PH 
had a fair to severe lung fibrosis, while the other three 
patients had none to limited lung fibrosis. Those three 
patients were diagnosed with PAH associated to IIM, 
WHO group 1 (patients 3, 5 and 9). In these patients, 
pulmonary fibrosis was either absent or present in <10% 
of the pulmonary surface (table 1). The remaining five 
patients with fair to severe pulmonary fibrosis were clas-
sified as PH caused by ILD (PH-ILD), WHO group 3.14
outcome
The total group of patients with IIM and PH revealed 
a mortality of four patients (44%) during a median 
observed follow-up of 16 months. Within 5 months of 
diagnosis of PH, two patients died (patients 4 and 5), one 
due to heart failure complicated by severe aorta valve 
stenosis. The other patients died as a result of respiratory 
failure complicated with pneumonia before vasoactive 
therapy could be started.
Vasoactive therapy was initiated in seven patients with 
precapillary PH (table 2). Therapy included the use 
of prostanoids, endothelin receptors antagonists and 
phosphodiesterase type-5 inhibitors. Follow-up informa-
tion was unavailable in one patient due to transfer to 
another hospital (patient 8). After the start of therapy, 
two patients revealed an increase of walking distance 
(18% and 9%) during 6 min walking test after 2 and 
12 months (patients 2 and 3). However, after initial 
improvement, one patient died 3 years later due to heart 
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failure (patient 3). Stabilisation of walking distance after 
6 months was observed in one patient. After 2 years, the 
patient died due to respiratory failure (patient 7). In one 
patient, pulmonary haemodynamics returned to normal 
after 1 year of therapy with bosentan (patient 6). The 
remaining two patients on PH therapy suffered from a 
slow progression on the WHO-FC (patients 1 and 9).
dIscussIon
In this clinical case series, we describe a group of nine 
patients with PH-IIM followed at two referral centres for 
PH. We found one patient to be classified as PH, WHO 
group 2 (left heart disease), five patients in WHO group 
3 (lung disease) and three patients in WHO group 1 
(PAH). Our study confirms previous results, indicating 
that the majority of the PH in IIM can be classified as 
PH-ILD, WHO group 3.6–12 However, PAH associated to 
IIM is a possibility, in this group occurring in 33% of the 
patients.
The pathogenesis of PAH in IIM is unknown; however, 
involvement of pulmonary vessels by diffuse infiltrative 
and inflammatory processes is likely to contribute.5 An 
Table 1 Clinical and haemodynamic characteristics of each patient at PH diagnosis
Characteristics Patient 1 Patient 2
Patient 
3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8
Patient 
9
Clinical characteristics PM PM PM PM 
overlap 
SLE
DM DM PM PM PM
  ANA + + + + + − + + –
  Anti-Jo1 + + – – NA + + – +
  Raynaud’s 
phenomenon
+ + – – – + + + –
  Arthritis (history) + + + – + + + + –
  Disease duration 
(years)
20.4 8.8 5.1 1.2 5.8 0.6 10 5.4 10.7
  WHO functional 
class
2 3 2 4 4 3 2 3 3
WHO PH group 3 3 1 2 1 3 3 3 1
HRCT scan
  Lung fibrosis on 
HRCT
+ + + NA – + + + +
  Wells score 2 3 2 NA 0 2 3 1 3
  Lung involvement 
(%)
70 70 10 NA 0 90 30 90 10
Extent of ILD Extensive Extensive Limited Extensive Limited Extensive Extensive Extensive Limited
Pulmonary function 
test
  TLC (% of 
predicted)
66 80 64 57 51 87 65 50 105
  DLCO (% of 
predicted)
66 53 68 NA 39 67 69 62 42
6 Min walking test (m) NA 143 420 NA NA NA 308 235 307
RHC
  Mean PAP (mm Hg) 45 40 66 41 60 32 25 33 52
  PCWP (mm Hg) 12 5 7 35 1 14 11 14 14
  Cardiac index (L/
min/m2)
NA NA 2.3 1.4 2.2 2.6 2.5 NA 2.1
  Cardiac output (L/
min)
NA 3.8 5.1 3.1 2.7 4.6 4.6 3.3 3.3
  PVR (dynes/s/cm5) NA 743 928 155 1749 315 242 461 109
 ANA, antinuclear antibody; DLCO, diffusing capacity for carbon monoxide; DM, dermatomyositis; ILD, interstitial lung disease; PAP, 
pulmonary arterial pressure; PCWP, pulmonary capillary wedge pressure; PH, pulmonary hypertension; PM, polymyositis; PVR, pulmonary 
vascular resistance; RHC, right heart catheterisation; SLE, systemic lupus erythematosus; TLC, total lung capacity; NA, not available.
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autopsy study among patients with PM found suggestive 
changes for PAH by encroachment of the pulmonary 
blood vessel lumen with medial smooth muscle hyper-
plasia.20 More recently, a Swedish study demonstrated 
that sera of anti-Jo1-positive patients with PM could acti-
vate endothelial cells in healthy lung tissue.21 Altogether, 
these findings reinforce the hypothesis of specific pulmo-
nary vascular involvement in the aetiology of PH among 
patients with IIM and the role of anti-tRNA synthetase 
autoantibodies such as anti-Jo1.5 12 20 21
Interestingly, two out of the three patients with 
PAH revealed the lowest diffusing capacity for carbon 
monoxide (DLCO) values in our study. This observation 
tends to suggest, conversely to PAH among patients with 
systemic sclerosis, that patients with IIM with PAH are 
associated with low DLCO values in pulmonary function 
test.22 23
Although small retrospective studies suggested that 
specific PAH therapy may be used in the presence of 
severe PH due to chronic lung disease, the benefit of this 
therapy still has to be demonstrated. In our cohort, initi-
ation of PAH treatment was performed on the discretion 
of the treating doctor, including six patients with ILD 
and one patient without ILD. Although our observations 
suggest that some of our patients seem to benefit from 
such an approach, the uncontrolled nature of this obser-
vational study does not allow to draw any conclusions on 
the effectiveness of such an approach in PAH.
A recent French observational study showed a 3-year 
survival of 58% in patients with PH antisynthetase.12 The 
overall mortality in our study was 44% which suggests that 
the presence of PH was associated with a worse survival.
The strength of our study is the novelty of reporting 
cases of PAH among patients with IIM with complete 
RHC data.
A limitation of our study is that all patients were 
recruited from two tertiary referral PH expert centres, 
which could have led to a selection bias. However, to 
study an uncommon complication (PH) in a rare disease 
(IIM) inevitably leads to multicentre recruitment at 
tertiary centres. Furthermore, limited serology data were 
available by which proper classification of the presence 
of antisynthetase syndrome and further determination of 
antinuclear antibody positivity was not possible.
Table 2 Follow-up of vasoactive therapy effect
Patient
Therapy at 
diagnosis
WHO-FC at 
PH diagnosis
Therapy 
adjustments
Observed 
follow-up 
(months)
Description 
outcome
WHO-FC at 
end follow-
up
Final 
outcome
1 S 2 S↑: 18 months
S↑: 36 months
36 Slow progression to 
WHO-FC 3
3 Alive
2 S 3 S + I: 12 
months
16 Remains at WHO-
FC 3 after iloprost 
therapy
3 Alive
3 B 2 B + S: 7 
months
B + S + T: 24 
months
36 Slow progression to 
WHO-FC 3
6-MWT at diagnosis 
420 m, at 8 
months 459 m, at 
28 months 390m
4 Death due 
to heart 
failure after 
36 months
6 B 3 B↑: 48 months 48 With bosentan 
no PH after 12 
months, after 48 
months progressive 
dyspnoea
NA Alive
7 S 2 Stop S: 8 
months
24 Exacerbation of 
PM after 8 months, 
↑ prednisone and 
start tacrolimus
4 Death due to 
respiratory 
failure after 
24 months
8 S 3 NA 0 Unknown due to 
transfer to other 
hospital
NA NA
9 A 3 Diuretics: 2 
months
12 Short hospitalisation 
after 2 months due 
to heart failure, after 
12 months stable in 
WHO-FC 3
3 Alive
A, ambrisentan; B, bosentan; I, iloprost inhalation; S, sildenafil; T, treprostinil; ↑, increase of dose; WHO-FC, WHO functional class; 6-MWT, 
6 min walking test; PM, polymyositis; NA, not available.
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In conclusion, in this study, we found the presence of 
ILD-PH in the majority (55%) of the selected patients 
with IIM and PH. Surprisingly, a relevant group (33%) 
of patients with IIM suffered from non-ILD-PH, which 
reflects the presence of PAH phenotype on which connec-
tive tissue disease itself plays a role in the aetiology. 
Vasoactive therapy could play a role in the treatment of 
patients with IIM and PAH phenotype. Altogether, this 
result should lead to more awareness among treating 
physicians that complaints of dyspnoea among patients 
with IIM could be related to PAH and not only ILD. 
Given the rarity of PH-IIM, a joined international effort 
is required to obtain more insights in the different PH 
phenotypes and the optimal treatment strategy of this 
disease.
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